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Abstract
Background: Strains of Plasmodium falciparum genetically resistant to chloroquine (CQ) due to the presence of
pfcrt 76T appear to have been recently introduced to the island of Madagascar. The prevalence of such resistant
genotypes is reported to be low (< 3%) when evaluated by conventional PCR. However, these methods are
insensitive to low levels of mutant parasites present in patients with polyclonal infections. Thus, the current
estimates may be an under representation of the prevalence of the CQ-resistant P. falciparum isolates on the
island. Previously, minority variant chloroquine resistant parasites were described in Malawian patients using an
isotopic heteroduplex tracking assay (HTA), which can detect pfcrt 76T-bearing P. falciparum minority variants in
individual patients that were undetectable by conventional PCR. However, as this assay required a radiolabeled
probe, it could not be used in many resource-limited settings.
Methods: This study describes a digoxigenin (DIG)-labeled chemiluminescent heteroduplex tracking assay (DIG-
HTA) to detect pfcrt 76T-bearing minority variant P. falciparum. This assay was compared to restriction fragment
length polymorphism (RFLP) analysis and to the isotopic HTA for detection of genetically CQ-resistant parasites
in clinical samples.
Results: Thirty one clinical P. falciparum isolates (15 primary isolates and 16 recurrent isolates) from 17 Malagasy
children treated with CQ for uncomplicated malaria were genotyped for the pfcrt K76T mutation. Two (11.7%)
of 17 patients harboured genetically CQ-resistant P. falciparum strains after therapy as detected by HTA. RFLP
analysis failed to detect any pfcrt K76T-bearing isolates.
Conclusion: These findings indicate that genetically CQ-resistant P. falciparum are more common than previously
thought in Madagascar even though the fitness of the minority variant pfcrt 76T parasites remains unclear. In
addition, HTAs for malaria drug resistance alleles are promising tools for the surveillance of anti-malarial
resistance. The use of a non-radioactive label allows for the use of HTAs in malaria endemic countries.
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Drug-resistant Plasmodium falciparum malaria is a major
global public health challenge since anti-malarial use
plays a pivotal role for malaria control [1,2]. Identifica-
tion of molecular markers associated with drug resistance
and the development of molecular methods to detect
these mutations in parasite samples from patients has
allowed for the use of large scale population surveys to
infer the efficacy of anti-malarials [3]. In addition, surveil-
lance based on these markers is being implemented to
guide national anti-malarial policies in many countries.
However, strong associations between molecular markers
and clinical outcomes have not been found systematically
[1,4].
Currently used techniques and protocols for monitoring
anti-malarial resistance based on molecular markers may
be inadequate. These methods may fail to detect the emer-
gence of drug resistance mutations in a population due to
a lack of sensitivity that is inherent in the method [5-7].
Among the chief reasons for this is the polyclonality of
malaria infections in highly endemic areas [1,5,8,9]. Each
patient with a polyclonal infection harbours multiple dif-
ferent variants, some of which will represent minority
populations within that individual (< 20% of the total
parasite population). The term "minority variant" has
been used to describe these populations, whether drug
resistant or not, in other mixed population infections,
such as HIV. Most currently used malaria genotyping
methods are insensitive to small sub-populations of drug-
resistant parasites (drug-resistant minority variants) in
mixed infections [5,7]. Thus, conventional genotyping
methods may under estimate the true prevalence of a
mutation in a population by missing patients who har-
bour minority variant drug-resistant parasites and, there-
fore, delay appropriate anti-malarial policy changes.
In contrast, heteroduplex tracking assays (HTAs), which
rely on gel mobility shifts to detect single nucleotide pol-
ymorphisms (SNP), are sensitive to minority variants and
are quantitative for the relative frequencies of resistant
and sensitive parasite variants in a patient. These assays
have been used frequently to describe drug-resistant
minority variants in HIV. In addition, they have been used
to describe drug-resistant minority variant malaria in
Malawi and to estimate the complexity of P. falciparum
malaria infections [5,6,8-10]. Thus, the use of HTAs for
monitoring drug resistance mutations in P. falciparum
may provide a more accurate evaluation of resistance.
However, current HTAs rely on isotopic labels for detec-
tion of the heteroduplexes, which makes them impractical
in most resource-poor settings. In order for them to be
used widely, non-isotopic HTA probes are needed.
Previously, an isotopic multi-site-specific HTA (MSS-
HTA) was used to describe the presence of minority vari-
ant chloroquine (CQ) resistant parasites in patients from
Malawi, where the prevalence of the pfcrt 76T mutation
has decreased dramatically since the withdrawal of CQ
[5]. Minority-variant pfcrt 76T bearing parasites were com-
mon even though, after the withdrawal of chloroquine,
the mutation was undetectable by standard PCR. How-
ever, no one has ever looked for minority variants while
drug resistance is newly emerging. Unlike Malawi, CQ has
been used on the island of Madagascar since 1945 and
remains a commonly used anti-malarial for in-home
treatment of fever [11]. Despite this fact, CQ-resistant P.
falciparum strains harbouring pfcrt 76T were not detected
on the island until recently [11]. This may have been due
to the geographic isolation of the country [12]. However
there is significant concern about the continued introduc-
tion of drug resistant parasites from surrounding islands
to Madagascar. A recent survey of passengers arriving at
the seaport and airport of Mahajanga City, the location of
most travel between Madagascar and the Comoros, found
high levels of pfcrt 76T (80.1%), dhfr 108N (95.0%) and
pfmdr-1 86Y (99.3%) in passengers arriving with PCR
detected malaria [12]. Interestingly, the clinical efficacy of
CQ in Madagascar has declined despite the lack of the pfcrt
76T mutation among the parasites, with efficacy rates as
low as 66% [13]. Thus, the epidemiology of CQ resistant
malaria in Madagascar provides a unique opportunity to
evaluate the use of HTAs to study the emergence of a
known drug resistance mutation.
In this paper, a new digoxigenin (DIG)-labeled heterodu-
plex tracking assay (DIG-HTA) is described, which uses
chemiluminescence or chemifluorescence, for the detec-
tion of the pfcrt 76T mutation. This represents the initial
development of HTAs appropriate for widespread use in
anti-malarial resistance surveillance, in an attempt to
track the emergence of mutant pfcrt bearing parasites in
Madagascar. Like the MSS-HTA, this assay is multi-site-
specific and can distinguish the two major CQ resistant
haplotypes of P. falciparum [5]. The DIG-HTA was com-
pared to the MSS-HTA in clinical samples previously
assayed from Malawi to determine the sensitivity and spe-
cificity of the assay to detect minority variants. The DIG-
HTA, MSS-HTA, and restriction fragment length polymor-
phism (RFLP) analysis were then used to evaluate clinical
samples from Malagasy children who took part in CQ
therapeutic efficacy trials as part of the activities of the
Réseau d'Etude de la Résistance du Paludisme (RER- a
national network for the surveillance of malaria resistance
in Madagascar) [14].
Methods
Malaria genomic DNA stocks
Plasmodium falciparum genomic DNA used for the devel-
opment of the DIG-HTA was supplied by MR-4 (ATCC,
Manassas, VA). The P. falciparum strain 3D7 (MRA-102G)
was used for wild type DNA. Two mutant pfcrt strains werePage 2 of 11
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contains the CVIET resistant haplotype, based on the
amino acid sequence from codon 72 to codon 76, while
strain 7G8 contains the SVMNT resistant haplotype.
Generation of the DIG-labeled HTA probe
The methods for the probe generation, including site
directed mutagenesis, probe screening and insertion into
the pT7 Blue vector (Novagen, Inc., Madison, WI), have
been described previously [5]. A single stand of the probe
was then labeled with a DIG-labeled nucleotide using Kle-
now fragment. Briefly, the pfcrt-pT7 Blue probe-vector
construct was harvested using the Hispeed Plasmid Maxi
Kit (Qiagen, Valencia, CA). Harvested plasmid was stored
at -20°C until use. Ten micrograms of pfcrt-pT7 Blue plas-
mid construct was digested for one hour with BamHI
(New England Biolabs, Beverly, MA) at 37°C and end-
labeled in the same buffer by filling in the overhang using
5 μl of labeling master mix incubated at room tempera-
ture for 15 minutes [50 μM DIG-dUTP (Roche, Man-
nheim, Germany), 50 μM dGTP (Promega, Madison, WI),
50 μM dCTP, 50 μM dATP, 10 mM dithiothreitol, and 5
units of Klenow fragment (New England Biolabs)]. The
reaction was halted by heat inactivation at 75°C for 15
minutes. The DIG-labeled probe was then cleaved from
the plasmid construct by digestion with PstI for 1 hour at
37°C. The labeled probe was then separated from the vec-
tor by agarose gel electrophoresis and purified with the
QIAquick gel extraction kit (Qiagen). The labeled probe
was stored at 4°C until use.
Heteroduplex tracking assay
The DIG-HTA was performed under the conditions noted
by Ngrenngarmlert et al with some modifications [9]. PCR
amplification of malaria DNA was carried out using prim-
ers and conditions already described [5]. An annealing
reaction consisting of 8 μl of PCR product (control or clin-
ical sample), 1 μl of 10× annealing buffer (1 M NaCl, 100
mM Tris-HCL, pH 7.5, 20 mM EDTA), 2 μl of 6× loading
dye, 0.3 μl 100 pmol CRT HTA F primer, 0.3 μl 100 pmol
CRT HTA R primer, and 0.4 μl of DIG-labeled probe was
heated to 95°C for 4 minutes and cooled at room temper-
ature for 5 minutes. The annealed heteroduplexes were
then separated on a non-denaturing 20% polyacrylamide
minigel (Invitrogen, Carlsbad, CA) in 1% Tris-borate-
EDTA (TBE) buffer using an Xcell Sure Lock Mini Cell
(Invitrogen). All gels were run at a constant current of 17
mA for 2.5 hours per gel. The following controls were used
on all gels: water, a non-template control PCR reaction,
and PCR reactions from wild type and mutant DNA
stocks. The DNA heteroduplexes were then transferred to
positively charged Nylon membrane with a pore size of
0.45 μm (Invitrogen) using the Xcell II Blot Module (Inv-
itrogen) in 0.5% TBE buffer. Electroblotting was done at
constant voltage (30 V per gel) for 1 hour. Heteroduplexes
were fixed to the membrane using an Ultra Lum UV
crosslinker (Ultra Lum, Inc., Claremont, CA) at 120,000
μJoules/cm2.
Chemiluminescent and chemifluorescent detection of 
heteroduplexes
As the heteroduplexes were already labeled with a DIG-
labeled probe, no probing step is needed for the mem-
brane. Chemiluminescent detection of the heterodu-
plexes was carried out per the protocol of the Roche DIG
Luminescent Detection Kit (Roche). After addition of the
chemiluminescent substrate, disodium 3-(4-methox-
yspiro {1,2-dioxetane-3,2'-(5'-chloro)tricyclo
[3.3.1.13,7]decan}-4-yl)phenyl phosphate (CSPD), mem-
branes were incubated at 37°C for 5 minutes to enhance
the chemiluminescent reaction. For autoradiograhic
detection, the membrane was exposed to Hyperfilm ECL
(GE Health care, Ltd., Buckinghamshire, UK) for 10 min-
utes and then developed. For the development of the
assay, some chemiluminescent gels were also evaluated
using a LAS-3000 imaging system (Fujifilm, Cypress, CA).
Images were captured at 10 minute exposures and were
processed using Multi Gauge v3.1 software (Fujifilm).
The assay was also evaluated for chemifluorescent detec-
tion. The protocol for chemiluminescence was followed
until the addition of the CSPD substrate. Instead, ECF
substrate for Western Blotting (GE Healthcare) was added
to the development folder using 24 μl/cm2 membrane.
The membranes were incubated for 5 minutes at room
temperature and were imaged using a Molecular Dynam-
ics Storm 860 (GE Healthcare) and analysed using Image-
Quant v5.2 software (GE Healthcare).
Assay design for minority variant detection
The DIG-HTA was run against mixtures of control DNA in
quadruplicate. Differing proportions of wild type
genomic DNA and CVIET resistant haplotype genomic
DNA were mixed to a final sample concentration of 0.1
ng/μl. The sensitivity of the assay was determined by vis-
ual inspection for the presence of bands along the dilu-
tion series. If a band was not visible to the eye, or only
visible in one of the replicates, it was not counted. The
assay was tested for chemiluminescent detection, using
both autoradiographs and the LUM-3000, as well as
chemifluoresecent detection.
In order to evaluate the accuracy of quantitative analysis
of band intensity, the dilution series were evaluated as fol-
lows. Autoradiographs of the series detected by chemilu-
minescence were scanned into .jpeg files. The relative
intensity of the two bands in each lane was determined
using ImageJ (NIH, Bethesda, MD) as described in the
documentation. This dilution series was also evaluated for
band intensity after imaging by a LAS-3000 (Fujifilm)Page 3 of 11
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band was determined by measuring the AUC-BG/mm2
(AUC: area under the curve, BG: background) and the rel-
ative intensity of the two bands was then determined for
each lane. The chemifluorescent dilution series was quan-
tified using ImageQuant v5.2 software according to the
manufacturer's instructions.
To determine if detection remained linear over multiple
concentrations, a serial dilution of stock 3D7 DNA was
also evaluated by chemiluminescence. The samples were
evaluated at 5 minute, 10 minute and 15 minute expo-
sures and quantified as above. To account for variations in
detection between gels, the ratio (intensity of a sample/
intensity of 1 ng/μl sample) was plotted relative to the
concentration of the sample.
Determination of sensitivity and specificity for minority 
variants in clinical samples
Twenty four P. falciparum isolates from Malawi initially
analysed by a radiolabeled MSS-HTA were re-analysed
using the DIG- HTA for the presence of minority variant
parasites [5]. These samples were known to contain
minority variants and their presence had previously been
documented by cloning and sequencing [5]. The samples
were collected from pregnant women as part of a pilot
randomized open label efficacy study of intermittent pre-
ventative treatment in pregnancy (IPTp) at rural health
clinics. The diversity of these infections, as well as a
description of the cohort, study design and informed con-
sent, has been described elsewhere [5,15]. The DIG-
labeled HTA was carried out in duplicate on these sam-
ples, using the chemiluminescent method with autoradi-
ographic detection. Samples were considered to contain
minority variant parasites if bands corresponding to
mutant heteroduplexes were visible to the eye in both rep-
licates.
Detection of minority variants in clinical samples
Thirty one clinical P. falciparum isolates from 17 patients
were analysed by the DIG-HTA and MSS-HTA for the pres-
ence of minority variant pfcrt bearing parasites. The sam-
ples were collected from consenting patients involved in
the assessment of CQ efficacy as part of RER activities
between 2002 and 2004 in Sainte Marie and Tsiroano-
mandidy, Madagascar – prior to the use of insecticide-
treated bed nets. Tsiroanomandidy, in the Midwestern
foothills, was characterized by mesoendemic malaria
[16]. The island of Sainte Marie on the eastern coast was
characterized by hyperendemic malaria [16]. The average
age of the patients was 80 months (range: 14 to 311
months), with an average parasitaemia of 15,860 tropho-
zoites/μl of blood (range: 88–128,000). In total, 16 recur-
rent isolates and 15 initial primary (D0) isolates were
examined. The DIG-HTA was carried out as noted above
for chemiluminescence with autoradiographic detection.
Band intensity was quantified as above. The method for
the MSS-HTA has been described elsewhere [5]. Samples
containing minority variant parasites were PCR amplified
and cloned as described by the Topo TA cloning kit (Inv-
itrogen). One hundred colonies from each sample were
screened by colony real time PCR as previously described
[5]. All colonies that contained mutant DNA and a selec-
tion of colonies containing wild-type DNA were
sequenced at the University of North Carolina-Chapel
Hill Automated DNA Sequencing Facility.
RFLP analysis for pfcrt K76T
All samples found to contain mutant DNA by HTA, as well
as a selection of pure wild type samples, were analysed by
a RFLP assay that has been used previously in the litera-
ture [17].
Results
Like the previously described MSS-HTA, the DIG-HTA
probe formed heteroduplexes with differing mobilities
when bound to wild type P. falciparum DNA amplicons
(Figure 1, Panel A, Lane C) and to mutant DNA amplicons
from the two major resistant haplotypes: SVMNT (data
not shown) and CVIET (Figure 1, Panel A, Lane D). The
sensitivity of the DIG-HTA for minority variants was
determined using artificial mixtures of know quantities of
wild type and mutant P. falciparum genomic DNA. The
assay was tested using three different detection methods:
1) chemiluminescence with autoradiography (Figure 1,
Panel A), 2) chemiluminescence with direct detection
using a cooled charge coupled device (CCD) camera (Fig-
ure 1, Panel B), and 3) chemifluorescence with direct
detection using a phosphorimager. The assay was able to
reliably detect populations of mutant parasites to a level
of 5% of the total population by all three methods (Table
1). At the 1% mutant level, the assay detected the presence
of minority variants in three of four replicates by autora-
diography and chemifluorescence. This level of mutant
parasite DNA was successfully detected in all four repli-
cates using the CCD camera.
The DIG-HTA was also able to reproducibly quantitate the
relative amount of DNA in the mixtures of genomic DNA
(Table 1). However, each of the detection methods has a
different dynamic range of detection. Therefore, different
concentrations of control P. falciparum DNA were ana-
lysed by each method to determine the dynamic range in
which quantification remains linear. Figure 2 shows the
relative intensity of the detected bands, expressed as a
ratio of the individual band intensity over the intensity of
the band from the highest concentration. This was done
in order to normalize for variability in detection between
the gels. Autoradiography (Figure 2, Panel A) has the nar-
rowest dynamic range. The signal for 0.1 ng of genomicPage 4 of 11
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exposure. However, at 5 minutes of exposure the lower
concentrations of DNA are not easily detectable. This
dynamic can potentially affect the ability to detect and
quantify minority variants (Figure 3). CCD cameras and
phosphorimagers have a larger dynamic range and detec-
tion remains linear over a larger range. Figure 2 Panel B
shows a 10 minute exposure to a CCD camera of a dilu-
tion series of DNA detected by chemiluminescence. The
relationship remains linear over the entire concentration
range (R2 = 0.9832) and over different exposure times [5
minute exposure (R2 = 0.9629) and 15 minute exposure
(R2 = 0.9679)].
Of 24 P. falciparum isolates from Malawi typed both by
MSS-HTA and DIG-HTA, 23 samples were successfully
amplified. Eight of the amplified samples contained
minority variant drug-resistant parasites detected by MSS-
HTA, ranging from approximately 2–5% of the parasite
population. The DIG-HTA successfully identified seven of
eight samples and no false positive samples were seen
(Figure 1, Panel C). Thus, among the samples successfully
amplified, the DIG-HTA had a sensitivity of 87.5% and
specificity of 100% when compared to the MSS-HTA.
The DIG-HTA and MSS-HTA were then applied to initial
and recurrent parasitaemia clinical samples from 17
malaria-positive Malagasy children. The results for each
patient are summarized in Table 2. Both assays success-
fully amplified 30 of 31 available samples. The lack of
available DNA prohibited the analysis of the other sam-
ples. In total, 2 (6.7%) of 30 samples [CI95%: 0.8–22%]
contained CVIET-resistant haplotype P. falciparum. Both
of these samples (136TDD Day 14 and 373STM Day 14)
contained minority variant drug-resistant parasites and
were from recurrent parasitaemia samples after initial
treatment with chloroquine. The mutant populations rep-
resented 1.7% and 2.9% of the recurrent parasite popula-
tion as detected by DIG-HTA (Table 2). These drug-
resistant minority variants were also found by MSS-HTA
(2.2% and 1.8%). Neither of these patients harboured
detectable CVIET-resistant haplotype parasites prior to
treatment. In total, 2 (11.7%) of 17 patients [IC95%: 1.5–
36.4%] carried pfcrt 76T-bearing parasites at some point
during their illness. RFLP analyses were unable to detect
pfcrt 76T-bearing parasites in any patient sample.
In order to confirm the presence of mutant DNA in the
samples, the two clinical samples containing minority
variants were cloned and 100 colonies from each were
screened by colony real time PCR [5]. Of the screened col-
onies 1 (1%) from each sample contained mutant DNA.
The mutant DNA-plasmid construct was harvested from
each of these colonies, as well as 4 wild-type plasmid con-
structs, and sent for sequencing. Both colonies with
detected mutant DNA contained the sequence of the
CVIET-resistant haplotype, while none of the wild-type
plasmid constructs contained the pfcrt K76T mutation.
Discussion
Until recently, malaria parasites containing mutant pfcrt
had not been described in Madagascar [11]. The pfcrt
mutation was reported to occur in 3.3% (6 of 183 sam-
ples) of P. falciparum isolates from the northern region
(Andapa) and from the Midwestern region (Tsiroano-
mandidy) as detected by RFLP analysis and confirmed by
sequencing [11]. In this study, by using HTAs, a higher
prevalence of CQ resistant P. falciparum was detected,
Table 1: Quantification of band intensity by the Digoxigenin(DIG)-labeled heteroduplex tracking assay
% Mutant DNA Autoradiography1
(ImageJ)
Chemiluminescent
(Multi Gauge)
Chemifluorescent
(ImageQuant)
Average % SD Average % SD Average % SD
50% 45.4 2.7 44.3 1.6 43.5 8.7
20% 29.2 2.5 26.0 2.2 16.2 5.0
10% 15.6 7.5 17.5 5.8 8.7 2.4
5% 8.1 2.2 9.0 3.8 5.4 2.2
1% 1.72 2.2 2.9 1.5 0.852 0.72
0.1% ND3 ND ND ND ND ND
1: Chemiluminescent detection.
2: Detected in 3 of 4 replicates.
3: Not detectedPage 5 of 11
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Digoxigenin(DIG)-labeled heteroduplex tracking assayFi ure 1
Digoxigenin(DIG)-labeled heteroduplex tracking assay. Panel A shows a dilution series of known mixtures of PCR 
amplified genomic DNA detected by chemiluminescence and autoradiography. Lanes A to D represent controls (water, NTC, 
Wild type DNA, and Mutant DNA). Mixtures of 50%, 20%, 10%, 5%, 1% and 0.1% mutant DNA are seen in lanes E to J, repec-
tively. Panel B shows a similar dilution series detected by chemiluminesence using the LAS-3000. Panel C shows clinical samples 
tested by chemiluminescence with autoradiography. Lanes A to D are controls in the same order as Panel A. Lanes E, F, K and 
L contain samples in duplicate that are pure wild type DNA. Lanes G, H, I and J contain samples in duplicate of mixed parasitae-
mias. The lowest band on all the gels represents the probe homoduplex.
Malaria Journal 2009, 8:47 http://www.malariajournal.com/content/8/1/47which exist as drug-resistant minority variants in children
previously treated with CQ. Among 17 children, 11.7%
(CI95%: 1.5 – 36.4%) carried minority variant drug resist-
ant parasites after treatment with CQ monotherapy. RFLP
analysis of these same samples failed to detect any con-
taining resistant parasites. Sequence analysis confirmed
the presence of minority variant drug-resistant parasites
carrying the CVIET haplotype. This haplotype, as well as
the CVIDT haplotype, were described upon the initial
characterization of pfcrt mutations in Madagascar [11].
The findings of this study raise several interesting ques-
tions. It appears that genotypically CQ-resistant parasites
occur only in a minority of patients in Madagascar. They
also occur as a minority population with-in individual
patients after therapy with CQ. Despite this, the clinical
efficacy of CQ has decreased significantly in Madagascar.
This means that the CVMNK CQ-sensitive haplotype is
the dominant haplotype detected among CQ failure cases
in Madagascar. This suggests one of two possibilities: 1)
the patients in this study failed due to other issues, such as
pharmacokinetics or 2) there is a pfcrt 76T independent
mechanism causing CQ failure among malaria parasites
in Madagascar. All the patients in this study were part of
RER clinical efficacy studies and received the WHO recom-
mended 25 mg/kg of CQ base over three days in directly
observed therapy. The patients underwent active surveil-
lance for recurrence of parasitaemia (asexual stages) on
days 1, 2, 3, 7, etc. These patients were considered clinical
treatment failures and did not undergo PCR correction.
Further evaluation is required to determine the cause of
clinical failures from patients with a dominate population
of CVMNK haplotype parasites in the recurrent sample,
including detailed pharmacokinetic, human and parasite
genetic studies.
In December 2005, the Malagasy national policy for the
treatment of uncomplicated malaria was revised aban-
doning CQ use and implementing artemisinin combina-
tion therapy (ACT) with artesunate plus amodiaquine as
first-line treatment and artemether plus lumefantrine as
second-line treatment. However, CQ remains available
commercially (even at the groceries) and pre-packaged
CQ is still recommended for in-home treatment of fever
(i.e. presumptive malaria cases) among children under
five. Even though the fitness of the genetically CQ-resist-
ant minority variant P. falciparum remains unclear, the
wide-spread presence of the pfcrt 76T allele could poten-
tially hamper the current policy. The mutation's presence
in conjunction with the pfmdr-1 86Y mutation has been
associated with failure to amodiaquine and previous stud-
ies of pfmdr-1 86Y in Madagascar have shown a prevalence
of 67.5% [16,18]. In addition, as the policy calls for a pro-
gressive introduction of ACT, the use of CQ will continue
for some time on the island. This will cause further eco-
logical pressure that could potentially promote the spread
of the pfcrt 76T allele. Thus, this finding of the occurrence
of minority variant of CQ- resistant P. falciparum is poten-
tially helpful by strengthening anti-malarial drug resist-
ance surveillance data. Larger studies would be needed to
confirm the distribution of minority variant resistant par-
asites on the island.
Previously, isotopic HTAs were used to document the
presence of minority variant drug resistant parasites in
Malawi (pfcrt 76T and dhfr 164L) [5,6]. This report
describes the first use of a non-isotopic labeled HTA probe
to successfully detect minority variant drug resistant P. fal-
ciparum parasites. This advance will allow this type of
method to be used in locations where it was previously
prohibited without a significant decrease in the sensitivity
of the assay relative to an isotopic label. However, the suc-
cess of measuring the abundance of DNA by HTA depends
on calibrating the signal from the DIG label over a usable
range of concentrations [19]. A CCD camera or phos-
phorimager typically allows signal to be detected in a lin-
ear fashion over a larger dynamic range (approximately
105) and sensitivity is generally increased [19]. The DIG-
HTA provided band intensities that remained linear when
detected by CCD camera over the usual concentration of
DNA extracted from filter paper blood spots (Figure 2,
Panel B). This becomes an issue when band intensity is
determined by autoradiography with densitometry, which
typically has a narrow dynamic range (approximately 102)
Dynamic range of imaging modalitiesFigure 2
Dynamic range of imaging modalities. Panel A shows 
the detected band intensities by autoradiography of a serial 
dilution of genomic DNA detected by the DIG-HTA. Intensi-
ties are expressed as the ratio of the sample's intensity 
divided by the intensity of the highest concentration sample 
in order to account for inter gel variability. The gels were 
exposed for 5 minutes (diamonds), 10 minutes (squares) and 
15 minutes (triangles). Panel B shows the same dilution series 
detected by CCD camera at 10 minutes (squares) with the 
best fit trend line (solid black line). The 5 minute and 15 
minute detections are not shown.
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low DNA concentrations, film exhibits reciprocity failure,
which means it requires a threshold level of signal before
an image is generated [19]. At higher DNA concentrations,
saturation effects mean the film darkening is not linear
with respect to the amount of light produced [19]. These
effects are seen in Figure 2, Panel A. Thus, when using film
based detection, it may be necessary to take several expo-
sures to ensure the blot falls within the linear range of the
film or adjust the starting amount or concentration of
DNA to a specific level. However, in resource poor set-
tings, the use of film-based detection eliminates the need
for expensive detection and analysis equipment ($20–
60,000 for a CCD camera or phosphorimager).
The use of radioactive probes for HTAs had several major
drawbacks. Firstly, disposal of radioactive waste in most
developing countries is not possible. Second, as the assays
used low energy isotopes (e.g. S35), long exposure times
ranging from 24 to 48 hours were required to detect a sig-
nal. Higher energy isotopes, such as I125 and P32 are more
hazardous and require special permits [20]. Lastly, once a
probe is labeled, radioactive decay limits the usable life
time of the probe [20]. The use of chemiluminescence or
chemifluorescence alleviates many of these problems.
These techniques are sensitive with fast detection (min-
utes instead of hours), and are quantifyable. Once probes
are bound to the label, they remain relatively stable and
do not suffer from decay as quickly as radiolabeled probes
[20]. The technology is safe and usable in almost any loca-
tion.
The International Atomic Energy Agency (IAEA) has sup-
ported a number of laboratories in Africa, including
Madagascar, to develop isotopic labeling techniques and
at these facilities isotopic HTAs would likely be the pre-
ferred method [21]. However, these facilities remain rela-
tively uncommon. In order for HTAs to gain wide spread
use, alternative labeling techniques are required. The DIG-
HTA potentially fulfills this niche. The fact that the label
can be detected by X-ray film means that this technique
would be easily implemented in a larger number of facil-
ities than would be possible for an isotopic HTA. The use
of a CCD camera or phosphorimager will allow for a
Saturation of autoradiographyFigure 3
Saturation of autoradiography. The figure shows a minority variant mixed sample exposed to autoradiography film for dif-
fering intervals. Lane A shows a 5 minute exposure where the mutant band is not visible. Lane B is a 10 minute exposure 
where the mutant band (see arrow) becomes visible. Lanes C and D show 15 and 20 minute exposures, respectively. In these 
lanes the background intensity begins to obscure the minority variant mutant band.Page 8 of 11
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but are not required in order to use the assay. It is unlikely
that access to these imaging systems will become wide-
spread in the near future.
HTAs appear to be a promising tool for studying the emer-
gence of drug resistance alleles, as well as a useful tool for
large scale molecular surveillance of anti-malarial resist-
ance. This is because they address several of the flaws
inherent in the currently used molecular methods and
genotyping protocols. First, HTAs are more sensitive for
minority variants than the currently used nested PCR tech-
niques [5,7]. Therefore they will not underestimate the
prevalence of drug resistance alleles in the population and
as shown in this study, can detect the emergence of drug
resistance alleles in a population earlier than nested PCR
[5]. However, the question remains: are drug-resistant
minority variants important clinically in an individual
host and do they affect drug treatment outcomes? Recent
data has shown that in vitro, mixed populations of P. falci-
parum containing resistant populations as low as 10%
could greatly impact drug treatment outcome [7]. The use
of HTAs for genotyping could help us confirm this finding
in vivo by being implemented in surveillance networks or
by evaluating large clinical trials that account for other
issues involved in parasite clearance, such as pharmacok-
Table 2: Chloroquine resistance DIG-HTA genotyping data of paired Malagasy Plasmodium falciparum samples
Initial Parasitaemia Recurrent Parasitaemia
Patient Parasitaemia1 % Wild Type % Mutant Day Parasitaemia1 % Wild Type % Mutant
36TDD 93250 100 0 14 2000 100 0
48TDD 750 100 0 14 100 100 0
60TDD 250 100 0 14 3500 100 0
62TDD 5000 100 0 14 500 100 0
85TDD 2000 100 0 14 250 100 0
99TDD 11000 100 0 12 5325 100 0
117TDD 750 100 0 12 750 100 0
135TDD 128000 100 0 14 240 DNA2 DNA
136TDD 11750 100 0 14 8500 98.3 1.74
121TDD 20000 100 0 -3 - - -
106STM -3 - - 14 88 100 0
114STM -3 - - 14 50000 100 0
233STM 15720 100 0 14 2320 100 0
273STM 1250 100 0 14 1200 100 0
313STM 15720 100 0 14 2320 100 0
315STM 2480 100 0 14 1061 100 0
373STM 54240 100 0 14 1600 97.1 2.95
1: Trophozoites per microliter
2: Did not amplify.
3: No DNA available for sample.
4: The MSS-HTA detected 2.2% mutant parasites in this sample. RFLP detected no mutant parasites.
5: The MSS-HTA detected 1.8% mutant parasites in this sample. RFLP detected no mutant parasites.Page 9 of 11
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a quantitative evaluation of the relative size of sensitive
and drug resistant parasite populations in an individual
patient. This information can then be used to calculate the
relative frequency of drug resistance alleles in the popula-
tion which can help model the time to drug failure [3,22-
24]. This issue has several consequences that were recently
reviewed by Hastings and Smith, who have proposed the
use of a computer based model (MalHaploFreq) of haplo-
type frequency as part of anti-malarial resistance surveil-
lance [3]. In addition, the selection coefficient, or fitness,
driving the increase in anti-malarial resistance can only be
measured by serial evaluation of frequency. The issues of
fitness and frequency and their involvement in the spread
of anti-malarial resistance were also recently reviewed
[3,23,24]. Thus, HTAs allow for direct measurement in
vivo of the major factor involved in emergence of drug
resistance and fitness of specific resistance alleles.
Conclusion
In conclusion, HTAs appear to be a promising technique
for studying the emergence of drug resistance in P. falci-
parum and for use in molecular surveillance of anti-malar-
ial resistance. The advance of using a non-radioactive
probe label will allow for these assays to be used in
resource limited settings where radioisotopes are prohib-
ited. In this initial study, the biomarker for CQ resistance,
pfcrt 76T was found to be more common than previously
reported in Madagascar and exists as minority variants in
the population. Thus, the presence of drug-resistant
minority variants may be a "marker" for the introduction
and emergence of new resistance alleles in a population
when parasite frequency is still extremely low in the pop-
ulation. In addition, the ability of HTAs to quantitate par-
asite populations would allow for evaluation of parasite
frequency in the population and more accurate calcula-
tions of the spread of drug resistance. Serial evaluation of
mutant parasite frequency may allow for a more accurate
prediction of time to anti-malarial failure, and in an indi-
vidual patient, allow for estimation in vivo of fitness gains
or losses of mutations.
In the future, the use of HTAs in molecular surveillance
networks, such as RER in Madagascar or the WorldWide
Antimalarial Resistance Network (WWARN), could
potentially provide a valuable early warning system for
detecting the emergence of genotypic resistance to anti-
malarials earlier than standard conventional PCR
[4,14,25]. Further work is needed in developing assays for
other important resistance loci, evaluation of these tech-
niques in larger studies, and implementing these tech-
niques in the field. In particular, if resistance mutations
associated with ACT failure can be identified, HTAs would
provide a chance to detect the spread of resistance more
quickly and allow for intervention in a timelier manner.
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